Nls pharmaceutics announces positive results from study ko-943 demonstrating mazindol reduces fentanyl-induced reward in animal models

Non-opioid, multi-mechanism profile positions mazindol as a differentiated asset in addiction therapeutics favorable results support potential expansion into high-value markets beyond adhd and narcolepsy zurich , april 15, 2025 /prnewswire/ -- nls pharmaceutics ltd. (nasdaq: nlsp) (nasdaq: nlspw) ("nls" or the "company"), a swiss clinical-stage biopharmaceutical company focused on developing innovative therapies for central nervous system (cns) disorders, today announced positive results from study ko-943, a preclinical investigation evaluating the efficacy of mazindol in mitigating fentanyl-induced conditioned place preference (cpp) in mice.
NLSP Ratings Summary
NLSP Quant Ranking